SCHEMBL4523133

SCHEMBL4523133

NC(=O)c1ccc([CH]c2ccccc2)o1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.49
HDAC1 Q13547 1/20 0.49
LMNA P02545 4/20 0.44
MAPT P10636 3/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PLA2G10 O15496 1/20 0.38
PLA2G2A P14555 1/20 0.38
HSD17B10 Q99714 2/20 0.38
TSHR P16473 2/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
PARP1 P09874 1/20 0.38
CYP2C19 P33261 1/20 0.38
RECQL P46063 1/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13637612 0.75 ALDH1A1 (0.45) HDAC4HDAC1LMNAKDM4EALDH1A1
SCHEMBL17664006 0.73 ALDH1A1 (0.42) HDAC4HDAC1LMNAMAPTKDM4E
SCHEMBL20830186 0.73 ALDH1A1 (0.42) HDAC4HDAC1LMNAMAPTKDM4E
Methane SCHEMBL16742564 0.73 ALDH1A1 (0.44) HDAC4HDAC1LMNAKDM4EALDH1A1
SCHEMBL7140275 0.71 ALDH1A1 (0.54) LMNAMAPTKDM4EALDH1A1HPGD
SCHEMBL4522155 0.70 SLC9A1 (0.40) LMNAMAPTKDM4EALDH1A1HPGD
SCHEMBL4523501 0.69 PARP1 (0.44) LMNAMAPTKDM4EALDH1A1HPGD
SCHEMBL3742201 0.69 ALDH1A1 (0.52) LMNAMAPTKDM4EALDH1A1HPGD
SCHEMBL4163540 0.68 ALDH1A1 (0.68) LMNAMAPTKDM4EALDH1A1HPGD
SCHEMBL31210189 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054445-A1 Amide Substituted Quinolines ASTRAZENECA AB (SE) 2009-02-26 US claimed
EP-1981882-A1 AMIDE SUBSTITUTED QUINOLINES AstraZeneca AB (SE) 2008-10-22 EP claimed
WO-2007086799-A1 AMIDE SUBSTITUTED QUINOLINES ASTRAZENECA AB (SE) 2007-08-02 WO claimed
US-20090054445-A1 Amide Substituted Quinolines ASTRAZENECA AB (SE) 2009-02-26 US disclosed
EP-1981882-A1 AMIDE SUBSTITUTED QUINOLINES AstraZeneca AB (SE) 2008-10-22 EP disclosed
WO-2007086799-A1 AMIDE SUBSTITUTED QUINOLINES ASTRAZENECA AB (SE) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054445-A1 Amide Substituted Quinolines RECQL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-0 HDAC4 1247/4885HDAC1 503/4885LMNA 1719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.